Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Multicenter, Open-label, Phase II Study to Investigate the Efficacy and Safety of Multiple Doses of IMAB362 in Patients With Advanced Adenocarcinoma of the Stomach or the Lower Esophagus

NCT01197885 is registered in ClinicalTrials.gov with Ganymed Pharmaceuticals GmbH as lead sponsor.

NCT NCT01197885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01197885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Multicenter, Open-label, Phase II Study to Investigate the Efficacy and Safety of Multiple Doses of IMAB362 in Patients With Advanced Adenocarcinoma of the Stomach or the Lower Esophagus
Lead sponsor
Ganymed Pharmaceuticals GmbH
Phase
Phase 2
Overall status
Completed
Start date
September 3, 2010
Completion date
August 13, 2015
Enrollment
54 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors